Skip to main content

Frates James M's Form 4 filing

Amylyx Pharmaceuticals, Inc.AMLX · filed Nov 12, 2026

Accession no.
0001193125-26-458247
Filed
Nov 12, 2026, 4:00 PM ET
Trade date
Nov 9-10, 2026
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.21M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Frates James MCIK 0001235598Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 9, 2026Common StockMOption exerciseAcquired+20,000$6.88+$137,600253,625Direct
Nov 9, 2026Common StockSSaleDisposed−7,700$29.39F2−$226,292.99245,925Direct
Nov 9, 2026Common StockSSaleDisposed−12,300$30.11F3−$370,359.15233,625Direct
Nov 10, 2026Common StockMOption exerciseAcquired+20,000$6.88+$137,600253,625Direct
Nov 10, 2026Common StockSSaleDisposed−12,800$30.32F4−$388,107.52240,825Direct
Nov 10, 2026Common StockSSaleDisposed−7,200$30.97F5−$222,982.56233,625Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 9, 2026Common StockMOption exerciseDisposed−20,000$0.00$0343,835Direct
Nov 10, 2026Common StockMOption exerciseDisposed−20,000$0.00$0323,835Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.81 to $29.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.82 to $30.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.86 to $30.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.905 to $31.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)